Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Up 6.6% – Should You Buy?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) traded up 6.6% on Tuesday . The stock traded as high as $26.09 and last traded at $25.81. 60,826 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 362,893 shares. The stock had previously closed at $24.21.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DMRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. Wedbush reaffirmed an “outperform” rating and set a $35.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. TD Cowen initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They issued a “buy” rating for the company. HC Wainwright assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 11th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Up 3.2%

The stock has a market capitalization of $1.54 billion, a P/E ratio of -4.48 and a beta of 1.46. The firm’s 50 day simple moving average is $23.73 and its two-hundred day simple moving average is $25.50.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, equities research analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DMRA. Janus Henderson Group PLC bought a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $40,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at approximately $49,000. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at approximately $76,000. Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $266,000. Finally, Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $6,574,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.